Photobiomodulation Therapy for Non-exudative Age-related Macular Degeneration.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and clinical literature without systematic review methodology.
PubMed 39710905 · doi:10.1097/IIO.0000000000000543
What was done
Narrative review evaluating the biological mechanisms and clinical trial evidence for photobiomodulation therapy (PBT) in non-exudative (dry) age-related macular degeneration (AMD). The review summarizes preclinical pathway data (mitochondrial function, retinal inflammation, wound healing) and human trial outcomes assessing visual function and retinal anatomy.
What was found
The abstract reports no numerical values, effect sizes, or statistical metrics. It qualitatively notes that clinical trials report improvements in functional parameters (visual acuity, contrast sensitivity) and anatomical features (drusen volume, geographic atrophy area).
Why it matters
Treatment options for intermediate dry AMD remain largely limited to nutritional supplements and lifestyle adjustments. PBT represents a potential non-invasive modality targeting mitochondrial dysfunction and chronic inflammation.
Limits
This is a narrative review without systematic search protocols, risk of bias assessment, or quantitative pooling. The underlying evidence base is limited by small sample sizes, heterogeneous treatment protocols, and restricted study populations.